| pubmed-article:21459795 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21459795 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:21459795 | lifeskim:mentions | umls-concept:C0023467 | lld:lifeskim |
| pubmed-article:21459795 | lifeskim:mentions | umls-concept:C0040739 | lld:lifeskim |
| pubmed-article:21459795 | lifeskim:mentions | umls-concept:C1096776 | lld:lifeskim |
| pubmed-article:21459795 | lifeskim:mentions | umls-concept:C0023981 | lld:lifeskim |
| pubmed-article:21459795 | lifeskim:mentions | umls-concept:C0206012 | lld:lifeskim |
| pubmed-article:21459795 | lifeskim:mentions | umls-concept:C0936012 | lld:lifeskim |
| pubmed-article:21459795 | lifeskim:mentions | umls-concept:C0205171 | lld:lifeskim |
| pubmed-article:21459795 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:21459795 | pubmed:dateCreated | 2011-7-1 | lld:pubmed |
| pubmed-article:21459795 | pubmed:databankReference | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21459795 | pubmed:abstractText | Background Allogeneic hematopoietic cell transplantation is considered the preferred post-remission therapy in patients with acute myeloid leukemia cytogenetically defined as being at high risk. To substantiate evidence for allogeneic hematopoietic cell transplantation in first complete remission in these high-risk patients we performed a landmark analysis within a single prospective multicenter treatment trial. DESIGN AND METHODS: By the time of analysis, 2,347 patients had been accrued into the AMLCG 99 trial between 1999 - 2007. Out of this population, 243 patients under 60 years old fulfilled the criteria for high-risk cytogenetics. Landmark analyses were performed with a control cohort, who remained in first complete remission at least the median time from complete remission to transplantation in the intervention group. RESULTS: After standardized induction therapy, 111 patients under 60 years old achieved complete remission. A matched allogeneic donor was identified for 59 patients (30 sibling donors, 29 unrelated donors). Fifty-five patients received an allogeneic hematopoietic cell transplant after a median time of 88 days in first complete remission. Of the remaining 56 patients, 21 relapsed within 90 days after achieving first complete remission and for 7 patients with relevant comorbidities no donors search was initiated, leaving 28 patients given conventional post-remission therapy as the control cohort. The median follow-up of surviving patients was 60.4 months. Patients with an allogeneic donor had substantially better 5-year overall and relapse-free survival rates than the control group (48% versus 18%, P=0.004 and 39% versus 10%, P<0.001, respectively). A survival benefit from transplantation was evident regardless of donor type, age and monosomal karyotype. Conclusions Beyond evidence available for subgroups of high-risk patients, the findings of this study establish in a broader manner that allogeneic hematopoietic cell transplantation is a preferable consolidation treatment for patients with acute myeloid leukemia and high-risk cytogenetics. The study was registered at Clinicaltrials.gov as NCT00266136. | lld:pubmed |
| pubmed-article:21459795 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21459795 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21459795 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21459795 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21459795 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21459795 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21459795 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21459795 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21459795 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21459795 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21459795 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21459795 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21459795 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21459795 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21459795 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21459795 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21459795 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21459795 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21459795 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21459795 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21459795 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21459795 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21459795 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21459795 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21459795 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21459795 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21459795 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21459795 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21459795 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21459795 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21459795 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21459795 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21459795 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21459795 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21459795 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:21459795 | pubmed:issn | 1592-8721 | lld:pubmed |
| pubmed-article:21459795 | pubmed:author | pubmed-author:BerdelWolfgan... | lld:pubmed |
| pubmed-article:21459795 | pubmed:author | pubmed-author:KienastJoachi... | lld:pubmed |
| pubmed-article:21459795 | pubmed:author | pubmed-author:BeelenDietric... | lld:pubmed |
| pubmed-article:21459795 | pubmed:author | pubmed-author:HeineckeAchim... | lld:pubmed |
| pubmed-article:21459795 | pubmed:author | pubmed-author:BüchnerThomas... | lld:pubmed |
| pubmed-article:21459795 | pubmed:author | pubmed-author:HiddemannWolf... | lld:pubmed |
| pubmed-article:21459795 | pubmed:author | pubmed-author:SpiekermannKa... | lld:pubmed |
| pubmed-article:21459795 | pubmed:author | pubmed-author:HollerErnstE | lld:pubmed |
| pubmed-article:21459795 | pubmed:author | pubmed-author:Müller-TidowC... | lld:pubmed |
| pubmed-article:21459795 | pubmed:author | pubmed-author:Schwerdtfeger... | lld:pubmed |
| pubmed-article:21459795 | pubmed:author | pubmed-author:BraessJanJ | lld:pubmed |
| pubmed-article:21459795 | pubmed:author | pubmed-author:SillingGerdaG | lld:pubmed |
| pubmed-article:21459795 | pubmed:author | pubmed-author:ServeHubert... | lld:pubmed |
| pubmed-article:21459795 | pubmed:author | pubmed-author:StelljesMatth... | lld:pubmed |
| pubmed-article:21459795 | pubmed:author | pubmed-author:ArnoldRenateR | lld:pubmed |
| pubmed-article:21459795 | pubmed:author | pubmed-author:KolbHans JHJ | lld:pubmed |
| pubmed-article:21459795 | pubmed:author | pubmed-author:SauerlandMari... | lld:pubmed |
| pubmed-article:21459795 | pubmed:author | pubmed-author:BerningBjörna... | lld:pubmed |
| pubmed-article:21459795 | pubmed:author | pubmed-author:German AML... | lld:pubmed |
| pubmed-article:21459795 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21459795 | pubmed:volume | 96 | lld:pubmed |
| pubmed-article:21459795 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21459795 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21459795 | pubmed:pagination | 972-9 | lld:pubmed |
| pubmed-article:21459795 | pubmed:meshHeading | pubmed-meshheading:21459795... | lld:pubmed |
| pubmed-article:21459795 | pubmed:meshHeading | pubmed-meshheading:21459795... | lld:pubmed |
| pubmed-article:21459795 | pubmed:meshHeading | pubmed-meshheading:21459795... | lld:pubmed |
| pubmed-article:21459795 | pubmed:meshHeading | pubmed-meshheading:21459795... | lld:pubmed |
| pubmed-article:21459795 | pubmed:meshHeading | pubmed-meshheading:21459795... | lld:pubmed |
| pubmed-article:21459795 | pubmed:meshHeading | pubmed-meshheading:21459795... | lld:pubmed |
| pubmed-article:21459795 | pubmed:meshHeading | pubmed-meshheading:21459795... | lld:pubmed |
| pubmed-article:21459795 | pubmed:meshHeading | pubmed-meshheading:21459795... | lld:pubmed |
| pubmed-article:21459795 | pubmed:meshHeading | pubmed-meshheading:21459795... | lld:pubmed |
| pubmed-article:21459795 | pubmed:meshHeading | pubmed-meshheading:21459795... | lld:pubmed |
| pubmed-article:21459795 | pubmed:meshHeading | pubmed-meshheading:21459795... | lld:pubmed |
| pubmed-article:21459795 | pubmed:meshHeading | pubmed-meshheading:21459795... | lld:pubmed |
| pubmed-article:21459795 | pubmed:meshHeading | pubmed-meshheading:21459795... | lld:pubmed |
| pubmed-article:21459795 | pubmed:meshHeading | pubmed-meshheading:21459795... | lld:pubmed |
| pubmed-article:21459795 | pubmed:meshHeading | pubmed-meshheading:21459795... | lld:pubmed |
| pubmed-article:21459795 | pubmed:meshHeading | pubmed-meshheading:21459795... | lld:pubmed |
| pubmed-article:21459795 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21459795 | pubmed:articleTitle | Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial. | lld:pubmed |
| pubmed-article:21459795 | pubmed:affiliation | Department of Medicine A/Hematology and Oncology, University of Muenster, Albert-Schweitzer-Str. 33, D-48129 Muenster, Germany. stell-jes@uni-muenster.de | lld:pubmed |
| pubmed-article:21459795 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21459795 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:21459795 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:21459795 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:21459795 | pubmed:publicationType | Multicenter Study | lld:pubmed |
